Literature DB >> 9882288

Strain-specific neutralization of human cytomegalovirus isolates by human sera.

M Klein1, K Schoppel, N Amvrossiadis, M Mach.   

Abstract

Induction of an effective antibody response against human cytomegalovirus (HCMV) is an important defense mechanism since it is potentially capable of neutralizing infectious viruses. We have analyzed the extent of HCMV strain-specific neutralization capacity in human sera. Nine recent HCMV isolates and their corresponding sera were investigated in cross-neutralization assays. We observed differences, independent of the overall neutralization capacity, in the 50% neutralization titers of the sera against individual strains, differences that ranged from 8-fold to more than 60-fold. For one isolate, complete resistance to neutralization by two human sera was observed. The neutralization capacity of human sera was not influenced by the presence of various concentrations (up to 100-fold excess) of noninfectious envelope glycoproteins, an inherent contamination of virus preparations from recent HCMV isolates. This indicated that the decisive parameter for neutralization is the titer of the neutralizing antibodies and that neutralization is largely independent of the concentration of virus. Analysis with transplant patients revealed that during primary infection strain-specific and strain-common antibodies are produced asynchronously. Thus, our data demonstrate that the induction of strain-specific neutralizing antibodies is a common event during infection with HCMV and that it might have important implications for the course of the infection and the development of anti-HCMV vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882288      PMCID: PMC103907     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Human cytomegalovirus glycoproteins.

Authors:  W J Britt; M Mach
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

2.  Cytomegalovirus glycoprotein B groups associated with retinitis in AIDS.

Authors:  D H Shepp; M E Match; A B Ashraf; S M Lipson; C Millan; R Pergolizzi
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

3.  The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies.

Authors:  K Schoppel; B Kropff; C Schmidt; R Vornhagen; M Mach
Journal:  J Infect Dis       Date:  1997-03       Impact factor: 5.226

4.  The role of antibody concentration and avidity in antiviral protection.

Authors:  M F Bachmann; U Kalinke; A Althage; G Freer; C Burkhart; H Roost; M Aguet; H Hengartner; R M Zinkernagel
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells.

Authors:  O B Spiller; B P Morgan; F Tufaro; D V Devine
Journal:  Eur J Immunol       Date:  1996-07       Impact factor: 5.532

6.  Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response.

Authors:  M Urban; M Klein; W J Britt; E Hassfurther; M Mach
Journal:  J Gen Virol       Date:  1996-07       Impact factor: 3.891

7.  Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. Human T cell leukemia/lymphoma virus type I (HTLV-I) and human cytomegalovirus (HCMV).

Authors:  G T Spear; N S Lurain; C J Parker; M Ghassemi; G H Payne; M Saifuddin
Journal:  J Immunol       Date:  1995-11-01       Impact factor: 5.422

Review 8.  Current prospects for immunization against cytomegaloviral disease.

Authors:  S P Adler
Journal:  Infect Agents Dis       Date:  1996-01

9.  Rhesus monkey responses to multiple injections of human monoclonal antibodies.

Authors:  P H Ehrlich; K E Harfeldt; J C Justice; Z A Moustafa; L Ostberg
Journal:  Hybridoma       Date:  1987-04

10.  Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.

Authors:  S P Adler; S E Starr; S A Plotkin; S H Hempfling; J Buis; M L Manning; A M Best
Journal:  J Infect Dis       Date:  1995-01       Impact factor: 5.226

View more
  31 in total

1.  Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.

Authors:  Ravit Arav-Boger; Sallie R Permar; Cody S Nelson; Diana Vera Cruz; Melody Su; Guanhua Xie; Nathan Vandergrift; Robert F Pass; Michael Forman; Marie Diener-West; Katia Koelle
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

2.  The genes encoding the gCIII complex of human cytomegalovirus exist in highly diverse combinations in clinical isolates.

Authors:  Lucy Rasmussen; Aimee Geissler; Catherine Cowan; Amanda Chase; Mark Winters
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Glycoprotein gene sequence variation in rhesus monkey rhadinovirus.

Authors:  Young C Shin; Leandro R Jones; Julieta Manrique; William Lauer; Angela Carville; Keith G Mansfield; Ronald C Desrosiers
Journal:  Virology       Date:  2010-02-20       Impact factor: 3.616

4.  Recombinant cytomegalovirus glycoprotein B vaccine: Rethinking the immunological basis of protection.

Authors:  Mark R Schleiss
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-06       Impact factor: 11.205

Review 5.  Role of antibodies in confining cytomegalovirus after reactivation from latency: three decades' résumé.

Authors:  Astrid Krmpotić; Jürgen Podlech; Matthias J Reddehase; William J Britt; Stipan Jonjić
Journal:  Med Microbiol Immunol       Date:  2019-03-28       Impact factor: 3.402

6.  Human Cytomegalovirus (HCMV) - Revised.

Authors:  Volkmar Schottstedt; Johannes Blümel; Reinhard Burger; Christian Drosten; Albrecht Gröner; Lutz Gürtler; Margarethe Heiden; Martin Hildebrandt; Bernd Jansen; Thomas Montag-Lessing; Ruth Offergeld; Georg Pauli; Rainer Seitz; Uwe Schlenkrich; Johanna Strobel; Hannelore Willkommen; Carl-Heinz Wirsing von König
Journal:  Transfus Med Hemother       Date:  2010-11-17       Impact factor: 3.747

Review 7.  Virion Glycoprotein-Mediated Immune Evasion by Human Cytomegalovirus: a Sticky Virus Makes a Slick Getaway.

Authors:  Thomas J Gardner; Domenico Tortorella
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-15       Impact factor: 11.056

8.  Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection.

Authors:  K Frenzel; J Lehmann; D H Krüger; L Martin-Parras; L Uharek; J Hofmann
Journal:  Med Microbiol Immunol       Date:  2013-12-15       Impact factor: 3.402

9.  Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines.

Authors:  K Frenzel; S Ganepola; D Michel; E Thiel; D H Krüger; L Uharek; J Hofmann
Journal:  Med Microbiol Immunol       Date:  2012-08       Impact factor: 3.402

10.  Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies.

Authors:  Thomas J Gardner; Cynthia Bolovan-Fritts; Melissa W Teng; Veronika Redmann; Thomas A Kraus; Rhoda Sperling; Thomas Moran; William Britt; Leor S Weinberger; Domenico Tortorella
Journal:  Clin Vaccine Immunol       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.